Teva has changed the dynamics of the generic NuvaRing (etonogestrel/ethinyl estradiol) market in the US after receiving approval for and launching its generic version of Merck & Co’s 0.120mg/0.015mg per day vaginal ring contraceptive.
The introduction of Teva’s version to the market adds a second true generic competitor alongside Amneal – which launched its version in December 2019 (Also see "Amneal Wins Race For US NuvaRing Rival " - Generics Bulletin, 13 December, 2019.) – as well as the authorized generic marketed by Prasco
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?